Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

0.20

Mkt cap

1.9M

Volume

673K

High

0.20

P/E Ratio

-0.05

52-wk high

7.39

Low

0.19

Div yield

N/A

52-wk low

0.16

In Monday's after-market session, several health care stocks showed significant movement. OpGen, Galecto, and Kyverna Therapeutics were among the top gainers, with shares increasing by 24.0%, 9.93%, and 9.19% respectively. On the losing end, Gritstone Bio saw a significant drop of 41.7%, followed by Aclarion and Qilian Intl Hldg Gr with declines of 17.08% and 7.1%. Other notable movements included Matinas BioPharma and Ontrak with increases, and BioVie, ABVC BioPharma, and Humana with decreases.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 8:31 pm

Aclarion, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for its patent application related to a system and method for diagnosing pain using magnetic resonance spectroscopy. This development could enhance Aclarion's position in the medical technology market by potentially offering a novel diagnostic tool.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 7:58 pm

In Friday's after-market session, several health care stocks showed notable movements. Cue Health, Aclarion, BioSig Technologies, OptiNose, SCWorx, and Avenue Therapeutics were among the gainers, with Cue Health leading with a 12.1% increase following its Q4 earnings release. On the downside, Molecular Templates, Better Therapeutics, PaxMedica, Aligos Therapeutics, Autolus Therapeutics, and Mersana Therapeutics experienced declines, with Molecular Templates dropping 12.7%. Earnings reports influenced some of these movements.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 9:33 pm

Aclarion, Inc. shares surged following the announcement of a European patent grant for a system and method in Magnetic Resonance Spectroscopy for diagnosing pain.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:04 pm

Aclarion, Inc. has received approval for European Patent Number EP3928695, which covers a system and method for diagnosing pain using magnetic resonance spectroscopy. This patent strengthens Aclarion's intellectual property portfolio and positions the company for further growth in the European market.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:01 pm

Pilgrim's Pride Corporation (NASDAQ:PPC) reported better-than-expected Q4 results with a 9.7% year-over-year sales growth to $4.528 billion and an adjusted EPS of 59 cents. Akili, Inc. (NASDAQ:AKLI) shares surged 116% after positive ADHD treatment trial results. Interactive Strength Inc. (NASDAQ:TRNR) rose 41% on a distribution deal with WOODWAY. Agiliti, Inc. (NYSE:AGTI) gained 29% after announcing a private acquisition by THL Partners. Aclarion, Inc. (NASDAQ:ACON), Intuitive Machines, Inc. (NASDAQ:LUNR), and Venus Concept Inc. (NASDAQ:VERO) saw significant share price drops due to various challenges.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 7:30 pm

Freshpet, Inc. (NASDAQ:FRPT) shares surged 15.5% after reporting Q4 earnings and sales above estimates. Other stocks also moved significantly in Monday's mid-day session, with notable gainers including Akili, Inc. (NASDAQ:AKLI), ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), and MicroCloud Hologram Inc. (NASDAQ:HOLO), among others. Losers included Aclarion, Inc. (NASDAQ:ACON) and Venus Concept Inc. (NASDAQ:VERO).

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 6:57 pm

Aclarion, Inc. shares are trading lower following the announcement of a $3 million public offering. The move to raise capital through a public offering has led to a decrease in the stock price as investors react to the potential dilution of their shares.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 6:02 pm

In Monday's intraday session, several health care stocks experienced significant movements. Akili, ZyVersa Therapeutics, Ocean Biomedical, Krystal Biotech, Milestone Pharmaceuticals, and Butterfly Network were among the gainers, with Akili leading at a 121.1% increase. On the downside, Aclarion, Venus Concept, ThermoGenesis Holdings, Bone Biologics, NGM Biopharmaceuticals, and Concord Medical Services saw notable declines, with Aclarion dropping 63%. Market capitalizations varied widely among these companies, reflecting their diverse sizes and impacts within the health care sector.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:31 pm

U.S. stocks traded mixed with the Dow and NASDAQ seeing slight gains, while the S&P 500 edged lower. Consumer discretionary shares rose, while utilities fell. Akili, Inc., Interactive Strength Inc., and Agiliti, Inc. saw significant stock increases due to positive business developments. Conversely, Aclarion, Inc., Intuitive Machines, Inc., and Venus Concept Inc. experienced notable declines. Crude oil prices increased by 1%, and U.S. new home sales rose by 1.5% in January.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 5:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.